The findings arrive after a swirl of regulatory uncertainty surrounding the trivalent (three-strain) vaccine, mRNA-1010.

An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.

The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for approval of its new flu vaccine, which is its first using mRNA technology ...

Moderna's mRNA flu vaccine shows greater efficacy than conventional shots in a large trial, boosting hope for mRNA technology ...

The U.S. FDA has agreed to review Moderna’s mRNA flu vaccine after initially declining, as next-generation RSV vaccines advance to address evolving viral strains. RSV continues to pose risks for older ...

Andrew Egger and Jonathan Cohn give their takes on the stunning back-and-forth at the FDA over Moderna’s new mRNA flu vaccine ...

These are strong results, and would likely make it hard for the FDA to refuse in a way that withstands arbitrary and capricious review,” said Dorit Reiss, a vaccine policy expert ...

FILE - A sign marks an entrance to a Moderna building in Cambridge, Mass., May 18, 2020. (AP Photo/Bill Sikes, File) FILE - A sign marks an entrance to a Moderna building in Cambridge, Mass., May 18, ...

If approved, this would be the first flu vaccine to use the same messenger RNA technology that powered Moderna’s COVID-19 shots. HealthDay News — In a sudden reversal, the US Food and Drug ...